Helping families by providing sequencing-based diagnoses of rare genetic diseases.
Invitae says the acquisitions, which total $72 million, will expand its diagnostics menu across every stage of an individual's life
Diagnostics Leveraging Next-Generation Sequencing Become Mainstream for Cancer and Rare Diseases
As noninvasive prenatal testing takes off, researchers look to the next frontier of single-cell analysis.
The researchers used a computational approach to analyze a data set of more than 116,000 individuals and 2.3 million human SNPs